CHAOSTOCOSMOS

Thursday, 2 July 2015

Fluge & Mella’s pre-trial study highlights life-changing potential of rituximab

Dr Øystein Fluge and Professor Olav Mella have published their new study in PLoS ONE. And though the study was not a blinded, placebo-controlled trial, the results are further evidence that rituximab is beneficial in some ME/CFS patients, and potentially life-changing for a substantial minority. The findings also give important new insights into the optimum dosing schedule to maintain those benefits in the long run.



Fluge & Mella’s pre-trial study highlights life-changing potential of rituximab

Pamela is a former accountant, recovering journalist and international cat herder, disabled and chronically sick with Myalgic Encephalomyelitis, Fibromyalgia and Cervical spondylosis, fluent in three languages; English, Spanish and Rubbish. Mostly writes in the latter. She likes Genealogy, Model Railways and Cats.

No comments:

Related Posts Plugin for WordPress, Blogger...
^ Top